AIM applies objective and evidence-based criteria, and takes individual circumstances and the local delivery system into account when determining the medical appropriateness of health …
Genetic Testing for Hereditary Cardiac Disease EFFECTIVE SEPTEMBER 4, 2022 Appropriate.Safe.Affordable 2022 AIM Specialty Health GEN05-0922.2
Genetic Testing for Single-Gene and Multifactorial Conditions EFFECTIVE SEPTEMBER 4, 2022 Appropriate.Safe.Affordable 2022 AIM Specialty Health
AIM Specialty Health - Remote Support Portal
RepresentativesSession Key Session Key BeyondTrust Remote Support
AIM will adopt all level 1 or 2A single and/or preferred imaging modality and frequency recommendations published by the National Comprehensive Cancer Network (NCCN), …
Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis EFFECTIVE SEPTEMBER 4, 2022 Appropriate.Safe.Affordable 2022 AIM Specialty Health GEN03-0922.2
Chromosomal Microarray Analysis, Whole Exome and Whole Genome Sequencing EFFECTIVE SEPTEMBER 4, 2022 Appropriate.Safe.Affordable 2022 AIM Specialty Health GEN07-0922.2
Genetic Testing | Carelon Clinical Guidelines and Pathways
ARCHIVED Carrier Screening in the Prenatal Setting and Preimplantation Genetic Testing 2024-01-01 to 06-29 (updated 2024-03-17)
Archived | Carelon Clinical Guidelines and Pathways
ARCHIVED Carrier Screening in the Prenatal Setting and Preimplantation Genetic Testing 2024-01-01 to 06-29 (updated 2024-03-17)
Genetic Testing for Hereditary Cancer Susceptibility EFFECTIVE SEPTEMBER 4, 2022 Appropriate.Safe.Affordable 2022 AIM Specialty Health GEN02-0922.2